Alimera Sciences Inc (ALIM) Releases Earnings Results, Misses Expectations By $-0.03 EPS

Alimera Sciences Inc (ALIM) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $-0.22 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $-0.19. The company posted revenue of $5.80 million in the period, compared to analysts expectations of $6.80 million. The company’s revenue was up 48.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.

Alimera Sciences Inc opened for trading at $2.2 and hit $2.2641 on the upside on Monday, eventually ending the session at $2.24, with a gain of 0.90% or 0.02 points. The heightened volatility saw the trading volume jump to 1,93,160 shares. Company has a market cap of $101 M.

In a different news, on Dec 17, 2015, Richard S Jr Eiswirth (COO and CFO) sold 46,669 shares at $2.31 per share price. According to the SEC, on Nov 16, 2015, C. Daniel Myers (President and CEO) sold 2,000 shares at $4.37 per share price. On Sep 8, 2015, Calvin W. Roberts (director) purchased 6,424 shares at $3.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Alimera Sciences Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye or retina. The Company’s commercial product is ILUVIEN which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States Austria Belgium the Czech Republic Denmark Finland France Germany Ireland Italy Luxembourg the Netherlands Norway Portugal Spain Sweden and the United Kingdom. In the United States ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries it is indicated for the treatment of vision impairment associated with DME.

Alimera Sciences Inc

Leave a Reply

Alimera Sciences Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alimera Sciences Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.